Kraštovaizdžio laboratorija, MB - company info and details
Company age: 1 y. 1 mo.
Company overview
Basic information
Company name
Kraštovaizdžio laboratorija, MB
Company code
307447875
Registered address
Vilnius, Architektų g. 56-23, LT-04111
Registration date
2025-09-29
Company age: 1 y. 1 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Email
Not disclosed
(personal)
Website
https://vitos.lt
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Small partnership
NACE activity
Landscape service activities
Ownership form
Private without foreign capital
Mažoji bendrija Kraštovaizdžio laboratorija
Company code: 307447875
Address: Vilnius, Architektų g. 56-23, LT-04111
Description
This description was generated by artificial intelligence.
Kraštovaizdžio laboratorija, MB (company code 307447875) is an operational private small partnership registered on 29 September 2025. It is classified as a micro company within the national private non-financial company sector, with a governance structure described as CEO only. The company is privately owned, with more than 50% of authorised capital held by Lithuanian natural and legal persons and no foreign investor capital. It is based in Vilnius, Vilniaus m. sav., Vilniaus apskr., at Architektu g. 56-23, LT-04111. Its main activity is EVRK O.81.30.00, Landscape service activities. For the 93-day financial period reported in 2025, the company generated revenue of €1.9K and recorded a net loss of €1.1K. At the end of the period, total assets stood at €859, short-term assets were also €859, liabilities were €1.9K, and equity was negative at €1.1K. The reported results indicate a very small operating base and a loss-making start to activity in its first financial period.
Download a detailed company report
Make confident decisions with all the information about Kraštovaizdžio laboratorija, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.